Efficacy and safety of albendazole 400 mg for 30 days compared to single dose of ivermectin in adult patients with low Loa loa microfilaremia: A non-inferiority randomized controlled trial

Luccheri Ndong Akomezoghe; Noé Patrick M’Bondoukwé; Denise Patricia Mawili Mboumba; Jacques Mari Ndong Ngomo; Bridy Chesly Moutombi Ditombi; Coella Joyce Mihindou; Roger Hadry Sibi Matotou; Valentin Migueba; Marielle Karine Bouyou Akotet

doi:10.1371/journal.pntd.0012383

June 20, 2025PLoS neglected tropical diseasesOpen Access

Efficacy and safety of albendazole 400 mg for 30 days compared to single dose of ivermectin in adult patients with low Loa loa microfilaremia: A non-inferiority randomized controlled trial

View Full Paper

Ask AI

Bookmark

Share

Key Points

To assess the efficacy and safety of daily albendazole for 30 days compared with a single dose of ivermectin in adults presenting with low Loa loa microfilaremia.
Randomized noninferiority trial conducted in northern Gabon from November 2021 to April 2022 among 48 adults (mean age 51 ± 13 years; 21 women, 27 men) diagnosed using direct blood examination and leukoconcentration.
Participants were randomly assigned to receive either oral albendazole 400 mg daily for 30 days (n=24) or a single oral dose of ivermectin 200 μg/kg (n=24), with adverse events and parasite levels evaluated from day 0 to day 30.
In the per-protocol analysis, mean microfilaremia decreased by 82.3% with albendazole and 90.4% with ivermectin (p < 0.001; risk difference 8.1%, 95% CI: 16.8 to -0.6%).
In the intention-to-treat analysis, mean microfilaremia decreased by 82.4% with albendazole and 90.8% with ivermectin (p < 0.001; risk difference 8.4%, 95% CI: 16.2 to 0.6%).
Circulating eosinophil levels declined by day 30 in both study groups, with no significant differences observed between the two regimens.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Randomized noninferiority trial reveals daily albendazole reduces microfilaremia in adults with low Loa loa infection, indicating its viability as an alternative to single-dose ivermectin.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Akomezoghe et al. (2025) studied this question.

synapsesocial.com/papers/6ab1dd3892cc8d7e6cb37521 https://doi.org/10.1371/journal.pntd.0012383

View Full Paper

Ask AI

Bookmark

Share

Efficacy and safety of albendazole 400 mg for 30 days compared to single dose of ivermectin in adult patients with low Loa loa microfilaremia: A non-inferiority randomized controlled trial

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Efficacy and safety of albendazole 400 mg for 30 days compared to single dose of ivermectin in adult patients with low Loa loa microfilaremia: A non-inferiority randomized controlled trial

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading